Clinical trials

This first-in-man clinical study in sepsis patients evaluated the safety, tolerability, pharmacokinetics and pharmacodynamic effects of intravenously administered M6229 in subjects suffering from sepsis. Pharmacodynamic effects of increasing doses of M6229 have been studied by assessing plasma levels of histone H3 and other biomarkers of inflammation and endothelial damage. Off-target pharmacological effects have been monitored, using continual reassessment method with escalation overdose control. The study has been performed at the University hospitals in Amsterdam and Maastricht, the Netherlands. 

More detailed information is available at the clinicaltrials.gov website & related press release.